Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the Company has disclosed that its intellectual property patent applications, filed in early 2021 for AP-188, included novel salt forms of DMT.
Mr. Moreau explains that a novel salt form of a drug is a new and separate structure from the original compound and is considered a new composition of matter. Many drug compounds’ core structures can often be paired with a salt. Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability.